Enanta Pharmaceuticals, Inc. (ENTA)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
13.45 USD
-0.33
(-2.395%) ⇩
(April 21, 2026, 2:32 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:50 a.m. EDT
ENTA is a high-risk speculative vehicle trading on clinical trial hype (hives drug, asthma data) and J.P. Morgan's upgrade; the long-term fundamentals are negative (no earnings, negative cash flow), making any upside entirely event-driven, so investors should treat this as event speculation rather than a fundamentally sound investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.054828 |
| AutoARIMA | 0.060245 |
| AutoETS | 0.060245 |
| MSTL | 0.065623 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 3.05 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.472 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 152.604 |
| Revenue per Share | 2.885 |
| Market Cap | 390,310,176 |
| Forward P/E | -6.43 |
| Beta | 1.00 |
| Profit Margins | -106.80% |
| Website | https://www.enanta.com |
As of April 19, 2026, 12:50 a.m. EDT: Options flow is heavily skewed bullish with significant out-of-the-money call open interest (OI) at strikes 17.5 and 22.5 by July 17, representing major positioning for upside. There is a notable bullish skew (OI calls > OI puts) and very low implied volatility (IV) for July calls (0.03), suggesting a 'pin risk' or low expected movement, yet the volume/OI concentration at high strikes indicates a 'buy the rumor/social media hype' strategy. Conversely, put activity is minimal and concentrated at deep OTM strikes (below 10), indicating no significant hedging against downside within the short term.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5054545 |
| Address1 | 4 Kingsbury Avenue |
| All Time High | 127.77 |
| All Time Low | 4.09 |
| Ask | 17.34 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 110,390 |
| Average Daily Volume3 Month | 170,101 |
| Average Volume | 170,101 |
| Average Volume10Days | 110,390 |
| Beta | 1.002 |
| Bid | 9.65 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 4.362 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.45 |
| Current Ratio | 4.442 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 13.77 |
| Day Low | 13.38 |
| Debt To Equity | 152.604 |
| Display Name | Enanta Pharmaceuticals |
| Earnings Call Timestamp End | 1,715,027,400 |
| Earnings Call Timestamp Start | 1,715,027,400 |
| Earnings Timestamp | 1,770,670,800 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -68,132,000 |
| Ebitda Margins | -1.0172 |
| Enterprise To Ebitda | -5.977 |
| Enterprise To Revenue | 6.08 |
| Enterprise Value | 407,220,576 |
| Eps Current Year | -2.125 |
| Eps Forward | -2.09167 |
| Eps Trailing Twelve Months | -3.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 607 0530 |
| Fifty Day Average | 13.6202 |
| Fifty Day Average Change | -0.17020035 |
| Fifty Day Average Change Percent | -0.012496171 |
| Fifty Two Week Change Percent | 150.54546 |
| Fifty Two Week High | 17.15 |
| Fifty Two Week High Change | -3.6999998 |
| Fifty Two Week High Change Percent | -0.21574344 |
| Fifty Two Week Low | 4.96 |
| Fifty Two Week Low Change | 8.49 |
| Fifty Two Week Low Change Percent | 1.7116935 |
| Fifty Two Week Range | 4.96 - 17.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,363,872,600,000 |
| Float Shares | 20,199,205 |
| Forward Eps | -2.09167 |
| Forward P E | -6.4302683 |
| Free Cashflow | -1,043,125 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 120 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 66,980,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04694 |
| Held Percent Institutions | 0.91415 |
| Implied Shares Outstanding | 29,019,344 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Long Business Summary | Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. |
| Long Name | Enanta Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 390,310,176 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_345286 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -71,537,000 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 399,886,560 |
| Number Of Analyst Opinions | 6 |
| Open | 13.77 |
| Operating Cashflow | -14,170,000 |
| Operating Margins | -0.60451 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 617 607 0800 |
| Previous Close | 13.78 |
| Price Eps Current Year | -6.3294115 |
| Price Hint | 2 |
| Price To Book | 3.083448 |
| Price To Sales Trailing12 Months | 5.8272643 |
| Profit Margins | -1.06804 |
| Quick Ratio | 4.345 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.32999992 |
| Regular Market Change Percent | -2.3947744 |
| Regular Market Day High | 13.77 |
| Regular Market Day Low | 13.38 |
| Regular Market Day Range | 13.38 - 13.77 |
| Regular Market Open | 13.77 |
| Regular Market Previous Close | 13.78 |
| Regular Market Price | 13.45 |
| Regular Market Time | 1,776,796,365 |
| Regular Market Volume | 41,258 |
| Return On Assets | -0.13467 |
| Return On Equity | -0.60012 |
| Revenue Growth | 0.098 |
| Revenue Per Share | 2.885 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,019,344 |
| Shares Percent Shares Out | 0.0735 |
| Shares Short | 2,133,058 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,187,043 |
| Short Name | Enanta Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.088 |
| Short Ratio | 13.03 |
| Source Interval | 15 |
| State | MA |
| Symbol | ENTA |
| Target High Price | 20.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 18.5 |
| Target Median Price | 20.0 |
| Total Cash | 185,848,992 |
| Total Cash Per Share | 6.404 |
| Total Debt | 193,183,008 |
| Total Revenue | 66,980,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.531025 |
| Two Hundred Day Average Change | 1.9189749 |
| Two Hundred Day Average Change Percent | 0.16641842 |
| Type Disp | Equity |
| Volume | 41,258 |
| Website | https://www.enanta.com |
| Zip | 2,472 |